We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
Read MoreHide Full Article
Key Takeaways
Curaleaf revenues fell 9% YoY to $310M in Q1 2025, hit by U.S. market saturation and pricing pressure.
International sales rose 74% YoY but still make up a small portion of total revenues for CURLF.
Despite higher margins and $26M in free cash flow, CURLF remains unprofitable amid growing competition.
Widely regarded as the largest cannabis operator by revenues, shares of Curaleaf Holdings (CURLF - Free Report) have been declining persistently over the past few years due to regulatory hurdles and intensifying competition.
While this Connecticut-based company has been aggressively cutting costs and expanding abroad, the core domestic market remains challenging to navigate, limiting the impact of its international progress.
Let’s delve into the company’s fundamentals to gain a better understanding of how to play the stock amid this price decline.
CURLF’s Domestic Weakness Eclipses International Gains
Curaleaf maintains a diversified business model in the cannabis space, spanning both retail and wholesale channels for both recreational and medical use, along with hemp-derived beverages. However, its top line continues to face pressure from a deteriorating domestic market.
In its first-quarter results of 2025, Curaleaf’s overall revenues fell by 9% year over year and 6% sequentially to $310 million. Although sales from the company’s international segment increased by 74% year over year, it still represents a relatively small portion of the total revenues. Most sales continue to come from Curaleaf’s domestic business, which remains under pressure due to the ongoing market saturation, pricing challenges and regulatory uncertainty.
Despite these headwinds, Curaleaf reported an adjusted gross margin of 50% (up 250 basis points YoY) and even managed to generate $26 million in free cash flow. While higher selling prices and operational efficiencies drove this improvement, it was still not enough to turn a profit. The company’s adjusted EBITDA margin declined 180 basis points YoY to 21%.
Looking ahead, we expect the company to scale its international business and boost domestic profitability by focusing on high-margin formats, such as hemp-derived beverages and other products. The company’s multiple cost-saving initiatives could further improve margins.
Cutthroat Competition From Other Cannabis Players
Curaleaf is targeting an overcrowded market. It faces stiff competition from its peers — Aurora Cannabis (ACB - Free Report) , Canopy Growth (CGC - Free Report) and Tilray Brands (TLRY - Free Report) — all of which are also pursuing international expansion and cost optimization strategies, making the competitive landscape even tougher.
As CURLF gains ground in Europe and Australia, competitive responses from Aurora Cannabis, Canopy Growth and Tilray Brands could intensify.
CURLF Stock Performance and Estimates
Shares of Curaleaf Holdings have plunged 46% year to date against the industry’s 7% rise, as seen in the chart below.
Image Source: Zacks Investment Research
Loss estimates for 2026 and 2027 have widened over the past 60 days.
Image Source: Zacks Investment Research
How to Play CURLF Stock?
While Curaleaf’s push into the THC beverages via its Select brand demonstrates strategic foresight, the persistent decline in its core domestic business makes it a risky bet in the near term. Also, a proposed federal bill that could significantly restrict (or even ban) the majority of hemp-derived products was recently approved by a House committee, posing further regulatory uncertainty. With a Zacks Rank #4 (Sell), the stock offers limited upside and elevated risk for conservative investors.
Image: Bigstock
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
Key Takeaways
Widely regarded as the largest cannabis operator by revenues, shares of Curaleaf Holdings (CURLF - Free Report) have been declining persistently over the past few years due to regulatory hurdles and intensifying competition.
While this Connecticut-based company has been aggressively cutting costs and expanding abroad, the core domestic market remains challenging to navigate, limiting the impact of its international progress.
Let’s delve into the company’s fundamentals to gain a better understanding of how to play the stock amid this price decline.
CURLF’s Domestic Weakness Eclipses International Gains
Curaleaf maintains a diversified business model in the cannabis space, spanning both retail and wholesale channels for both recreational and medical use, along with hemp-derived beverages. However, its top line continues to face pressure from a deteriorating domestic market.
In its first-quarter results of 2025, Curaleaf’s overall revenues fell by 9% year over year and 6% sequentially to $310 million. Although sales from the company’s international segment increased by 74% year over year, it still represents a relatively small portion of the total revenues. Most sales continue to come from Curaleaf’s domestic business, which remains under pressure due to the ongoing market saturation, pricing challenges and regulatory uncertainty.
Despite these headwinds, Curaleaf reported an adjusted gross margin of 50% (up 250 basis points YoY) and even managed to generate $26 million in free cash flow. While higher selling prices and operational efficiencies drove this improvement, it was still not enough to turn a profit. The company’s adjusted EBITDA margin declined 180 basis points YoY to 21%.
Looking ahead, we expect the company to scale its international business and boost domestic profitability by focusing on high-margin formats, such as hemp-derived beverages and other products. The company’s multiple cost-saving initiatives could further improve margins.
Cutthroat Competition From Other Cannabis Players
Curaleaf is targeting an overcrowded market. It faces stiff competition from its peers — Aurora Cannabis (ACB - Free Report) , Canopy Growth (CGC - Free Report) and Tilray Brands (TLRY - Free Report) — all of which are also pursuing international expansion and cost optimization strategies, making the competitive landscape even tougher.
As CURLF gains ground in Europe and Australia, competitive responses from Aurora Cannabis, Canopy Growth and Tilray Brands could intensify.
CURLF Stock Performance and Estimates
Shares of Curaleaf Holdings have plunged 46% year to date against the industry’s 7% rise, as seen in the chart below.
Loss estimates for 2026 and 2027 have widened over the past 60 days.
How to Play CURLF Stock?
While Curaleaf’s push into the THC beverages via its Select brand demonstrates strategic foresight, the persistent decline in its core domestic business makes it a risky bet in the near term. Also, a proposed federal bill that could significantly restrict (or even ban) the majority of hemp-derived products was recently approved by a House committee, posing further regulatory uncertainty. With a Zacks Rank #4 (Sell), the stock offers limited upside and elevated risk for conservative investors.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.